{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacogenomic+Study&page=2", "query": { "intervention": "Pharmacogenomic Study", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacogenomic+Study&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T06:31:51.093Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01907802", "title": "Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRAF Gene Mutation", "Hepatic Complication", "Renal Failure", "Solid Neoplasm" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-08-23", "completion_date": "2015-12-16", "has_results": false, "last_update_posted_date": "2018-08-14", "last_synced_at": "2026-09-27T06:31:51.093Z", "location_count": 17, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01907802" }, { "nct_id": "NCT00826540", "title": "Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Rectal Cancer" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2009-09", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-09-27T06:31:51.093Z", "location_count": 211, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 134 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00826540" }, { "nct_id": "NCT00445744", "title": "Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Myelodysplastic Syndromes", "de Novo Myelodysplastic Syndromes", "Essential Thrombocythemia", "Myelodysplastic Syndrome With Isolated Del(5q)", "Polycythemia Vera", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Secondary Myelofibrosis", "Untreated Adult Acute Myeloid Leukemia", "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "cytogenetic analysis", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 52, "start_date": "2006-12", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2018-01-02", "last_synced_at": "2026-09-27T06:31:51.093Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00445744" }, { "nct_id": "NCT00025363", "title": "Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alveolar Childhood Rhabdomyosarcoma", "Embryonal Childhood Rhabdomyosarcoma", "Embryonal-botryoid Childhood Rhabdomyosarcoma", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Childhood Rhabdomyosarcoma" ], "interventions": [ { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "tirapazamine", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "20 Years", "sex": "ALL", "summary": "Up to 20 Years" }, "enrollment_count": 150, "start_date": "2001-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-17", "last_synced_at": "2026-09-27T06:31:51.093Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025363" }, { "nct_id": "NCT01192815", "title": "Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "gene expression analysis", "type": "OTHER" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "biopsy", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" }, { "name": "polymorphism analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 2, "start_date": "2011-01", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-09-27T06:31:51.093Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192815" }, { "nct_id": "NCT06322238", "title": "Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pharmacogenomic Drug Interaction", "Side Effect of Drug", "Ineffective Drug Action", "Drug Metabolism, Poor, CYP2D6-Related", "Drug Metabolism, Poor, CYP2C19-Related" ], "interventions": [ { "name": "PGx panel test", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2024-12-01", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-09-27T06:31:51.093Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06322238" }, { "nct_id": "NCT04893395", "title": "Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pharmacogenetics", "Depressive Disorder, Major", "Medication Therapy Management" ], "interventions": [ { "name": "Pharmacogenomic Screening", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Auburn University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 0, "start_date": "2021-09-01", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2022-08-09", "last_synced_at": "2026-09-27T06:31:51.093Z", "location_count": 1, "location_summary": "Tuscaloosa, Alabama", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04893395" }, { "nct_id": "NCT03380819", "title": "The VetSeq Study: a Pilot Study of Genome Sequencing in Veteran Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rare Diseases", "Genetic Disease" ], "interventions": [ { "name": "Genome sequencing", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "VA Boston Healthcare System", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2, "start_date": "2017-12-29", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2023-04-26", "last_synced_at": "2026-09-27T06:31:51.093Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03380819" }, { "nct_id": "NCT02625207", "title": "THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "Maraviroc (Part 1)", "type": "DRUG" }, { "name": "Maraviroc (Part 2)", "type": "DRUG" }, { "name": "Darunavir/cobicistat (Part 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 47, "start_date": "2015-11-06", "completion_date": "2016-03-26", "has_results": true, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-09-27T06:31:51.093Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02625207" }, { "nct_id": "NCT03508570", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Peritoneal Neoplasm", "Malignant Retroperitoneal Neoplasm", "Metastatic Cervical Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Fallopian Tube Carcinoma", "Metastatic Malignant Female Reproductive System Neoplasm", "Metastatic Ovarian Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Peritoneal Carcinomatosis", "Platinum-Refractory Fallopian Tube Carcinoma", "Platinum-Refractory Malignant Female Reproductive System Neoplasm", "Platinum-Refractory Ovarian Carcinoma", "Platinum-Refractory Primary Peritoneal Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Malignant Female Reproductive System Neoplasm", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Malignant Female Reproductive System Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacokinetic Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 26, "start_date": "2018-09-21", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-09-27T06:31:51.093Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03508570" } ] }